Despite the important roles of MERTK and FLT3 in immune cell development, little effort has been done to fully elucidate the effect that new generation of MERTK or FLT3 inhibitors may have on a prime component the anti-tumor immune response, namely cytotoxic CD8+ T cells. Here, CD8A is linked to neoplasm.